FLEXTRADE-SYSTEMS
20.3.2023 15:31:27 CET | Business Wire | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset order and execution management systems, announces the appointment of Rajiv Shah as Head of Sales in EMEA for its sell-side OEMS, FlexOMS.
FlexOMS, the flagship OMS platform within FlexTrade's suite of sell-side solutions, is designed to boost trading efficiency by simplifying the complexities of today's trading workflows. The open-architecture trading solution supports high-touch and low-touch businesses by providing a unified multi-asset platform across cash, program trading, futures & options, ETF, swaps, fixed income, and foreign exchange workflows.
In this newly created role, Rajiv will drive FlexTrade's business strategy and growth of the solutions to trading desks within EMEA. Rajiv brings over 30 years of experience in financial technology with a proven track record in designing and executing sales and business growth strategies across the front and middle-office trading space within enterprise-grade software firms. This has most recently included organizations such as Cosaic, where he was Global Head of Sales and, in several senior leadership roles during 20 years at Fidessa, including most notably, Head of Sales and Account Management of the EMEA business across all Fidessa products and services.
Rajiv Kedia, Principal & Associate Founder at FlexTrade, noted: "For over 25 years FlexTrade has led the way in delivering innovative OEMS solutions to the buy and sell side communities. We feel that FlexOMS's powerful and unique combination of innovative, open, and scalable technology underpinned by FlexTrade's tailored white glove service experience and domain expertise addresses a big need in the EMEA sell-side landscape.
We are already seeing great growth and interest and are investing heavily in this market. A key component of executing our growth strategy for the solution and business in EMEA is ensuring we have the best people in place. With his long-proven track record, there is no one better than Rajiv Shah to help us move forward."
Rajiv Shah, Head of Sales, Sell-Side Solutions, FlexTrade EMEA, stated: "In today's constantly changing landscape, the sell side must work with an OMS technology partner whom they can trust and deliver an open approach to innovation. Choosing the correct solutions provider to deliver on these requirements is paramount to supporting their clients' businesses and navigating an increasingly competitive marketplace.
It's an exciting time to join FlexTrade. From a business perspective, the firm has a demonstrable track record in creating and growing long-standing customer relationships through first-class support and a client-first approach. Alongside this, the advanced capabilities of FlexOMS make it one of the most compelling offerings available within the OEMS space. "
About FlexTrade Systems Sell-Side Trading Solutions:
FlexTrade Systems is a global financial technology firm that aims to boost trading efficiency by simplifying the complexities of today's trading workflows by providing a unified, open-architecture multi-asset sell-side trading platform. FlexTrade achieves this by underpinning cutting-edge, API-rich technology with highly-specialized service and support for high touch and low touch businesses across cash, program trading, futures & options, ETF, swaps, and foreign exchange workflows. Whether the focus is market-making, agency, retail, or proprietary trading desks, FlexTrade can enhance straight-through processing for the complete order management lifecycle from order receipt and trading to middle and back-office workflows in a single modular technology platform.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom